Research Reports | Market Assessment
September 2014

Biomarkers for Emerging Biologics for Severe/Refractory Asthma

The use of biomarkers and personalized medicine is at a very early stage in asthma. Although most asthma patients can obtain disease control through treatment with available therapies, there remains a high unmet need for more-individualized therapies and therapeutic regimens that can be used in severe subpopulations of the heterogeneous asthma population.

Although severe/refractory patients represent only a subset of the asthma population, novel agents that target this patient segment have the potential to command price premiums given these patients’ level of unmet need. As a result, a series of biologics targeted at specific subpopulations of asthma patients (e.g., IL-5 inhibitors for eosinophilic asthma patients, IL-13 inhibitors for severe asthma patients with elevated periostin or dipeptidyl peptidase-4 [DPP-4]). These targeted agents are being developed with the intention of using them in patients who express a particular biomarker. The development of targeted biologics represents the most active space in asthma research.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports